Scrip Asks...What Does 2023 Hold For Biopharma? Part 1: The Funding Environment
Can Biotechs Weather The Ongoing Downturn Or Will There Be Carnage?
With valuations down and borrowing costs up, many industry insiders are expecting Darwinian scenes in biotech this year. Survival of the fittest is the order of the day: companies with riskier, less commercially defined propositions will struggle, while platform companies with multiple shots on strong goals will increasingly find favor in a more risk-averse environment.
